ERBB2 and breast carcinoma: ER+ and HER2+ breast cancer patients have achieved great therapeutic benefits through endocrine therapy (e.g., aromatase inhibitors, SERMs, and SERDs) [4] and anti-HER2 therapeutic antibodies (e.g., trastuzumab and pertuzumab) [5], respectively.